Moderna Sinks 6% on Citi Downgrade; Merck and Pfizer Stay Flat

Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is drawing attention Wednesday after Citigroup downgraded the biotech company to Sell from Hold, arguing that the recent rally has pushed the valuation well ahead of what its pipeline can reasonably support. Moderna sank 6% to $191.36 in early trading following the downgrade.

The move comes after an extraordinary run for Moderna, which had climbed nearly 590% in 2026 heading into Wednesday’s session. By comparison, the broader market and biotechnology benchmarks have delivered much smaller gains, highlighting just how much investor expectations around Moderna’s cancer-vaccine program have changed.

Moderna’s Citi Downgrade

Citi analyst Geoff Meacham lowered Moderna to Sell from Hold while raising the price target to $80 from $60. The higher target reflects updated sales and operating assumptions, yet the target remains far below Moderna’s recent trading level of about $203.46.

Citi’s concern centers on intismeran autogene, Moderna’s personalized cancer vaccine being developed with Merck’s Keytruda. Moderna and Merck recently reported that the combination improved recurrence prevention in melanoma, but detailed trial results have not yet been disclosed, leaving questions about how broadly the treatment could work across other cancers.

MRNA Versus Merck and Pfizer

The contrast with larger pharmaceutical peers is notable. Merck (NYSE:MRK) was recently trading around $149.11, up about 0.3%, while Pfizer (NYSE:PFE) was around $28.65, down roughly 0.2%, based on the latest available regular-session data.

Merck has a direct connection to the Moderna story because Merck’s Keytruda is being tested alongside intismeran. Pfizer, meanwhile, provides another large-cap pharmaceutical reference point, with Pfizer stock showing considerably less volatility than Moderna during the recent biotech rally.

What IBB and SPY Are Showing

The broader ETF picture also puts Moderna’s move into perspective. The iShares Biotechnology ETF (NASDAQ:IBB) rose 0.04%, while the SPDR S&P 500 ETF Trust (NYSE ARCA:SPY) gained 0.29%.

Those relatively modest moves contrast sharply with Moderna’s enormous recent swings. Moderna stock gained 6.98% on Sept. 24 and 12.27% on Sept. 21, while IBB and SPY have generally experienced much smaller daily moves over the same period.

What Moderna Investors Are Watching

Citi’s downgrade does not mean Moderna’s cancer program has failed. Meacham acknowledged that intismeran could become a leading melanoma treatment, but argued that the stock price increasingly assumes successful expansion into several additional tumor types and very large commercial sales.

The next major test could come with additional intismeran data expected at the European Society for Medical Oncology meeting in late October. For investors, the key issue may be whether forthcoming clinical results can support the lofty expectations now embedded in Moderna’s valuation, particularly after such a dramatic run.

Moderna stock‘s volatility Wednesday also illustrates why the stock can be difficult to evaluate using the day’s percentage move alone. Meanwhile, Merck, Pfizer, IBB, and SPY remained comparatively subdued, leaving investors to weigh a highly specific company catalyst against broader market conditions.

Contact [email protected] for any questions or corrections.